GlassScriptPhysician profile
Mia Chorney
NPI 1255705125
$78,700.73
in general payments reported to CMS, 2019-2025
29 companies · $4,328 in 2025
The $4,328 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,975 · 2022: $34K · 2023: $27K · 2024: $10K · 2025: $4,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $9,706 · Food and Beverage: $3,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,750.00 |
| Travel and Lodging | $9,706.00 |
| Food and Beverage | $3,326.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74,223.70 | 2021-2025 | Lifevest |
| Zoll Medical Corporation | $1,500.00 | 2025 | Defibrillator |
| Novartis Pharmaceuticals Corporation | $271.94 | 2021-2025 | |
| Itamar Medical INC | $255.80 | 2022-2023 | Watchpatone |
| Medtronic, INC. | $248.52 | 2021 | |
| Abbott Laboratories | $235.46 | 2021-2023 | Cardiomems |
| Kestra Medical Technology Services, INC. | $170.06 | 2022 | |
| Pfizer INC. | $160.90 | 2021-2025 | |
| W. L. Gore & Associates, INC. | $152.05 | 2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis |
| Astrazeneca Pharmaceuticals LP | $151.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $146.14 | 2021-2023 | |
| Cvrx, INC. | $145.39 | 2021 | |
| Alnylam Pharmaceuticals INC. | $142.05 | 2023 | Onpattro, Amvuttra |
| Impulse Dynamics (USA) INC. | $141.17 | 2023 | Optimizer |
| Boston Scientific Corporation | $139.80 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $91.79 | 2021-2025 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $89.92 | 2021-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $82.74 | 2021-2025 | Verquvo |
| Heartflow, INC. | $76.42 | 2024 | |
| Janssen Pharmaceuticals, INC | $68.84 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $63.89 | 2024-2025 | Wegovy |
| Bridgebio Pharma, INC. | $27.04 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $21.40 | 2021 | |
| Edwards Lifesciences Corporation | $18.90 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $18.81 | 2024 | Arcalyst |
| Preventice Services, LLC | $17.04 | 2021 | |
| Amgen INC. | $15.14 | 2023 | Repatha |
| Amarin Pharma, INC. | $12.52 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mia Chorney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.